Changing
the Lens.
Novel Molecules Inspired
by Overlooked Drugs
In 19th-century physics, the term “singularity” described points where traditional laws of physics no longer applied, symbolizing profound shifts in understanding.
At Singularity, we’re creating inflection points in drug discovery to leverage everyday remedies into new, breakthrough therapeutics.
We See Things Differently.
Singularity is a drug discovery-based research company dedicated to developing novel drug candidates to treat CNS disorders with unmet needs. By applying medicinal chemistry and phenotypic screening to non-regulated, overlooked, or “natural” remedies, we aim to develop new compounds with superior therapeutic potential that can be advanced along a regulatory pathway to better meet the needs of patients.
Singularity’s lead program is a platform established around novel analogs of the key metabolites of Kratom, a traditional therapy that is used to self-medicate a diverse range of CNS ailments by millions in North America and Southeast Asia.
We’re advancing a portfolio of novel therapeutics targeting areas of high unmet need with the potential for improved safety and efficacy.
Program One
Advancing a safer approach to acute pain management for fragile patients. Built on novel alkaloid-inspired compounds designed to deliver effective relief while reducing opioid-related risk.
Program Two
Advancing novel therapies for refractory and rare epilepsies where current treatments fall short. Designed to improve seizure control in patients who do not respond adequately to existing options.
Singularity’s founders have a successful track record identifying and executing on underappreciated drug discovery opportunities. Previously, they founded and led Mindset Pharma to exit to Otsuka Pharmaceuticals. Mindset was a drug discovery business focused on novel psychedelic inspired medicines. Mindset was sold to Otsuka Pharmaceuticals in 2023.